HF
ATOS icon

HRT Financial’s Atossa Therapeutics ATOS Stock Holding History

HRT Financial’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,129
Closed -$14K – 3163
2025
Q3 		$14K Sell
1,129
-5,211
-82% -$64.4K ﹤0.01% 2731
2025
Q2 		$78K Buy
+6,340
New +$75.8K ﹤0.01% 2247
2025
Q1 		– Sell
-2,100
Closed -$29K – 2508
2024
Q4 		$29K Buy
+2,100
New +$41K ﹤0.01% 2165
2024
Q2 		– Sell
-19,428
Closed -$524K – 2201
2024
Q1 		$524K Buy
+19,428
New +$312K ﹤0.01% 1232
2023
Q4 		– Sell
-1,943
Closed -$21K – 2299
2023
Q3 		$21K Buy
+1,943
New +$28.2K ﹤0.01% 2064
2022
Q3 		– Sell
-1,994
Closed -$32K – 2780
2022
Q2 		$32K Buy
+1,994
New +$31.4K ﹤0.01% 2559
2021
Q4 		– Sell
-16,234
Closed -$594K – 3164
2021
Q3 		$793K Buy
+16,234
New +$944K ﹤0.01% 1509

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HRT Financial's ATOS Position: Q4 2025 in Review

HRT Financial sold out of Atossa Therapeutics (ATOS) in Q4 2025, closing a stake of 1,129 shares — an estimated $14K sold.

HRT Financial first reported a position in ATOS in Q3 2021 and held it in 7 quarters. The position peaked at $793K in Q3 2021. 67 funds tracked by Wall St. Rank hold ATOS as of Q4 2025.

  • HRT Financial reported no remaining Atossa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 1,129 Atossa Therapeutics shares in Q4 2025, an estimated $14K.
  • HRT Financial first reported a position in Atossa Therapeutics in Q3 2021 and held it in 7 quarters.
  • HRT Financial's Atossa Therapeutics position peaked at $793K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.